#volagidemab is a novel #glucagon receptor #antagonist whose use in type1 #diabetes is associated with reduced glucose fluctuations, lower insulin requirement; reduced #ketoacidosis risk
It is a #game #changer in the field of diabetes management
nyaspubs.onlinelibrary.wiley.com/doi/full/10....